Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An interleukin-39 specific antagonistic protein and its application in the treatment of autoimmune diseases

A specific, interleukin-based technology, applied in the direction of allergic diseases, bone diseases, immunoglobulin, etc., can solve the problems of long course of disease and low cure rate, achieve obvious therapeutic effect, reduce pathological changes, reduce damage index and spleen index Effect

Inactive Publication Date: 2021-06-15
HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are more women than men in patients, more elderly than teenagers, and there is a genetic predisposition. This type of disease also has overlapping phenomena, that is, patients can suffer from more than one autoimmune disease, and the course of the disease is generally longer. Limitation; low cure rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An interleukin-39 specific antagonistic protein and its application in the treatment of autoimmune diseases
  • An interleukin-39 specific antagonistic protein and its application in the treatment of autoimmune diseases
  • An interleukin-39 specific antagonistic protein and its application in the treatment of autoimmune diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022]Example 1 Obtaining of 23R-gp130 protein coding gene

[0023] A fusion cDNA fragment encoding IL-23R receptor extracellular domain, Linker peptide (GGGGGSS), gp130 receptor extracellular domain, and Linker peptide (GGGGGSS) was obtained by using the method of whole gene synthesis, and the 5' end contains human Il -2 Signal peptide coding sequence. The synthesized DNA sequence was inserted into the recombinant plasmid pSBS1-Cloning Vector to obtain the pSBS1-23R-gp130 plasmid. The synthetic sequence is shown in SEQ ID No.6.

Embodiment 2

[0024] Example 2 RT-PCR amplification of human IgG1 Fc cDNA fragment

[0025] 1. Extraction of total RNA from human lymphocytes

[0026] Blood sample collection: Use a disposable anticoagulant vacuum blood vessel for blood collection, and the blood collection volume is generally 2ml.

[0027] 2. Isolation of lymphocytes

[0028] ① Extract lymphocytes. Take a 1.5ml sterile enzyme-free centrifuge tube, tube ①, first add 500μl lymphocyte separation solution; another 1.5ml sterile enzyme-free centrifuge tube, a vacuum tube containing 500μl blood sample and 500ul Hank's solution, 1:1 Mix the mixture to a total of 1ml. Then slowly add the mixed blood sample Hank's mixture into tube ① with lymphocyte separation solution. Centrifuge horizontally at 1500 rpm for 15 minutes at room temperature. ②After centrifugation, the liquid in the tube is divided into three layers, the upper layer is plasma and Hank’s solution, and the lower layer is mainly red blood cells and granulocytes. Th...

Embodiment 3

[0042] Example 3 Construction of IL23R-gp130-Fc protein coding gene recombinant plasmid

[0043] As mentioned above, the 5' end of the whole gene synthesis fragment 23R-gp130 is designed with a Sal I restriction site, and the 3' end is designed with a BamH I restriction site, so that the cDNA fragment of 23R-gp130 can be directly inserted into eukaryotic expression Vector pSelect-Puro (purchased from Invivogen, USA, see figure 2 ) in the multiple cloning site Sal I / BamH I, and insert the IgG1 Fc fragment into the multiple cloning site BamH I / Nhe I to obtain the IL23R-gp130-Fc fusion fragment. See its construction process image 3 ; The finally obtained pSelect-IL23R-gp130-Fc expression vector is as follows Figure 4 shown. Specific steps are as follows:

[0044] 1) Cut the 23R-gp130 sequence from the synthetic recombinant plasmid pSBS1-23R-gp130 with SalⅠ / BamHI, and perform SalⅠ / BamHI double enzyme digestion on the pSelect-Puro vector plasmid at the same time. The digest...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
purityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an interleukin-39-specific antagonistic protein, a gene encoding the protein, and its application in the treatment of autoimmune diseases. The present invention can inhibit its function in autoimmune diseases by combining with IL-39 . The experimental results show that the interleukin-39 specific antagonist protein has a significant therapeutic effect on MRL / lpr in lupus mice, can significantly reduce the injury index and spleen index of lupus mice, reduce the level of urinary protein and autoantibodies in mice, and alleviate the MRL / lpr Pathological changes in the kidney and spleen of lpr lupus mice, and the therapeutic effect is remarkable.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to an interleukin-39 specific antagonistic protein and its application in treating autoimmune diseases. Background technique [0002] Autoimmune diseases (AID) such as Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Sjögren's disease (Sjögren's syndrome or Sjögren's syndrome) Disease) is a disease in which the immune system positively responds to the host's own antigens, causing pathological damage to its tissues or organs, affecting its physiological functions, and eventually leading to various clinical symptoms. There are more women than men in patients, more elderly than teenagers, and there is a genetic predisposition. This type of disease also has overlapping phenomena, that is, patients can suffer from more than one autoimmune disease, and the course of the disease is generally longer. Limitation; low cure rate. Therefore, there is an urgent need fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62A61K38/17A61P29/00A61P19/02A61P37/02
CPCA61K38/00C07K16/2803C07K16/2866C07K2319/02C07K2319/30
Inventor 周晓雷朱重悦褚洁张世光邹卫
Owner HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com